Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Latest from City of Hope

ASCO and the entire oncology community are deeply saddened by the loss of colleague, friend, ASCO Board of Directors member, and geriatric oncology leader Arti Hurria, MD, FASCO.
Ravi Salgia, MD, PhD, Arthur & Rosalie Kaplan Chair in Medical Oncology, associate director for clinical sciences at City of Hope, discusses the FDA approval of lorlatinib for use in patients with ALK-positive metastatic non–small cell lung cancer.
Michael A. Caligiuri, MD, president of City of Hope National Medical Center, and Deana and Steve Campbell Physician-in-Chief Distinguished Chair, has been elected to the National Academy of Medicine, one of the highest honors in the fields of health and medicine.
Sumanta Kumar Pal, MD, a medical oncologist at City of Hope, discusses the frontline approval of nivolumab (Opdivo) and ipilimumab (Yervoy) for patients with metastatic renal cell carcinoma (RCC).
Karen Reckamp, MD, co-director, Lung Cancer and Thoracic Oncology Program, medical director, Clinical Research Operations, professor, Department of Medical Oncology & Therapeutics Research, thoracic oncologist, discusses current and emerging therapeutic strategies to target MET in non-small cell lung cancer.
Walker will lead patient care, nursing, ancillary and supportive service operations for the main Duarte campus and clinical network.
Sumanta Kumar Pal, MD, sheds light on the latest frontline therapeutic options for patients with mRCC and other advancements on the horizon.
Sumanta Kumar Pal, MD, associate clinical professor, Department of Medical Oncology and Therapeutics Research, co-director, Kidney Cancer Program, City of Hope, discusses the role of PD-L1 in metastatic renal cell carcinoma.
Publication Bottom Border
Border Publication